Focus: Bayer is a 100,000-person global pharmaceutical and chemical giant headquartered in Leverkusen, Germany, with a diversified portfolio across oncology, cardiovascular, hematology, and ophthalmology. As a publicly traded company (BAYRY), it combines legacy branded drugs with emerging biotech programs across multiple therapeutic areas.
Profile data last refreshed 2h ago · AI intelligence enriched 2mo ago
Stable — net -3 jobs in 30d
2 added, 5 removed. Backfill posture.
Bayer offers stable, large-scale pharma career opportunities with meaningful pipeline optionality, but revenue concentration risk and recent restructuring require careful timing evaluation.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Bayer
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Bayer's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Cornerstone revenue driver (34% of portfolio) with 10-year runway; guanylate cyclase stimulator in well-established indication.
Second-largest revenue contributor with 18-year LOE; AR inhibitor competing in crowded prostate cancer space with 53 clinical trials ongoing.
Mineralocorticoid receptor antagonist in high-unmet-need nephrology space; 40 clinical trials supporting broad CKD positioning.
Multi-indication kinase inhibitor facing LOE in 2032; significant pipeline development ongoing with 109 Phase 2 trials in metastatic colorectal cancer.
TRK inhibitor in precision oncology segment; 10 clinical trials supporting label expansion in rare NTRK-fusion tumors.
110 discontinued, 90 duplicate formulations not shown
+10 more products with revenue data
Bayer Counts the Cost of Litigation as a Supreme Court Verdict Dangles Over a Corporate Reshuffle - AD HOC NEWS
Bayer Counts the Cost of Litigation as a Supreme Court Verdict Dangles Over a Corporate Reshuffle AD HOC NEWS
Bayer extends partnership with Peking University to accelerate translation of scientific research and drive drug discovery and innovation - Global Times
Bayer extends partnership with Peking University to accelerate translation of scientific research and drive drug discovery and innovation Global Times
Bayer Nears a Tipping Point as Supreme Court, Drug Trials, and Management Overhaul Converge - AD HOC NEWS
Bayer Nears a Tipping Point as Supreme Court, Drug Trials, and Management Overhaul Converge AD HOC NEWS
Bayer positions China as an innovation engine in its global healthcare strategy - China Daily - Global Edition
Bayer positions China as an innovation engine in its global healthcare strategy China Daily - Global Edition
EMA validates Bayer’s asundexian application for ischaemic stroke - Pharmaceutical Technology
EMA validates Bayer’s asundexian application for ischaemic stroke Pharmaceutical Technology
EMA validates Bayer’s asundexian application for ischaemic stroke - Yahoo
EMA validates Bayer’s asundexian application for ischaemic stroke Yahoo
Showing 6 of 10 news items
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Source: state DOL filings, aggregated via Big Local News
Active restructuring presents near-term career uncertainty; monitor role stability and organizational changes before committing to multi-year assignments.
Recent peer-reviewed publications with author affiliations at this company
Global Perspective on the Evolution and Future of Pharmacovigilance: Deliverables from the 24th Annual Meeting of the International Society of Pharmacovigilance Celebrating 25 Years of Excellence.
Pharmacological treatments and clinical events in newly diagnosed heart failure patients stratified by ejection fraction in Japan.
+50 more products
+2 more
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo